DK0858804T3 - Anvendelse af rifaximin og farmaceutiske præparater indeholdende dette i behandlingen af diarré forårsaget af cryptosporidiosis - Google Patents

Anvendelse af rifaximin og farmaceutiske præparater indeholdende dette i behandlingen af diarré forårsaget af cryptosporidiosis

Info

Publication number
DK0858804T3
DK0858804T3 DK98101081T DK98101081T DK0858804T3 DK 0858804 T3 DK0858804 T3 DK 0858804T3 DK 98101081 T DK98101081 T DK 98101081T DK 98101081 T DK98101081 T DK 98101081T DK 0858804 T3 DK0858804 T3 DK 0858804T3
Authority
DK
Denmark
Prior art keywords
cryptosporidiosis
rifaximin
treatment
pharmaceutical preparations
preparations containing
Prior art date
Application number
DK98101081T
Other languages
English (en)
Inventor
Patrizio Ferrari
Antonella Ferrieri
Pietro Caramello
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Application granted granted Critical
Publication of DK0858804T3 publication Critical patent/DK0858804T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
DK98101081T 1997-02-14 1998-01-22 Anvendelse af rifaximin og farmaceutiske præparater indeholdende dette i behandlingen af diarré forårsaget af cryptosporidiosis DK0858804T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97BO000064A IT1290679B1 (it) 1997-02-14 1997-02-14 Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.

Publications (1)

Publication Number Publication Date
DK0858804T3 true DK0858804T3 (da) 2002-07-08

Family

ID=11341939

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98101081T DK0858804T3 (da) 1997-02-14 1998-01-22 Anvendelse af rifaximin og farmaceutiske præparater indeholdende dette i behandlingen af diarré forårsaget af cryptosporidiosis

Country Status (12)

Country Link
US (1) US5886002A (da)
EP (1) EP0858804B1 (da)
JP (1) JP4848083B2 (da)
KR (1) KR100436243B1 (da)
CN (1) CN1115146C (da)
AT (1) ATE218342T1 (da)
DE (1) DE69805672T2 (da)
DK (1) DK0858804T3 (da)
ES (1) ES2178048T3 (da)
HU (1) HU224592B1 (da)
IT (1) IT1290679B1 (da)
PT (1) PT858804E (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
EP1620420A2 (en) * 2003-04-30 2006-02-01 The Institutes for Pharmaceutical Discovery, LLC Substituted carboxylic acids
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
HUE025306T2 (hu) * 2006-08-02 2016-01-28 Salix Pharmaceuticals Inc Sugárterápia által okozott bélgyulladás kezelésére irányuló módszer
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
CN102164599B (zh) 2008-09-26 2014-07-23 Aska制药株式会社 预防和/或治疗功能性胃肠障碍的药剂
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
EP2350096B1 (en) 2008-10-02 2019-12-11 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
MX2012005883A (es) 2009-11-23 2012-10-09 Cipla Ltd Composicion topica en espuma.
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2011110930A2 (en) * 2010-03-10 2011-09-15 Lupin Limited Rifaximin ready-to-use suspension
KR20140029356A (ko) 2010-09-13 2014-03-10 시플라 리미티드 약학 조성물
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
US9938298B2 (en) 2014-05-12 2018-04-10 Alfa Wassermann S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
EP3160467B1 (en) * 2014-06-30 2021-03-10 Salix Pharmaceuticals, Inc. Combination comprising rifaximin and cyclosporine for use in the treatment of bowel diseases
WO2016138118A1 (en) * 2015-02-26 2016-09-01 Jaguar Animal Health, Inc. Use of croton- or calophyllum-derived proanthocyanidin polymers or botanical extracts in combination with rifaximin for the treatment of diarrhea in non-human animals
CA2988930A1 (en) * 2015-06-10 2016-12-15 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
AU2017343886B2 (en) 2016-10-14 2023-07-06 Cipla Limited Pharmaceutical compositions comprising rifaximin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter

Also Published As

Publication number Publication date
CN1115146C (zh) 2003-07-23
KR19980071348A (ko) 1998-10-26
KR100436243B1 (ko) 2004-08-25
ITBO970064A1 (it) 1998-08-14
HUP9800115A3 (en) 2000-04-28
ITBO970064A0 (it) 1997-02-14
EP0858804B1 (en) 2002-06-05
ES2178048T3 (es) 2002-12-16
ATE218342T1 (de) 2002-06-15
DE69805672D1 (de) 2002-07-11
PT858804E (pt) 2002-10-31
IT1290679B1 (it) 1998-12-10
US5886002A (en) 1999-03-23
DE69805672T2 (de) 2003-01-23
HU9800115D0 (en) 1998-03-30
CN1214244A (zh) 1999-04-21
JP4848083B2 (ja) 2011-12-28
JPH10226645A (ja) 1998-08-25
HU224592B1 (hu) 2005-11-28
EP0858804A1 (en) 1998-08-19
HUP9800115A1 (hu) 1999-06-28

Similar Documents

Publication Publication Date Title
DK0858804T3 (da) Anvendelse af rifaximin og farmaceutiske præparater indeholdende dette i behandlingen af diarré forårsaget af cryptosporidiosis
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
CO4340622A1 (es) Nuevos macrociclos bis-indolil maleimida
TR200101567T2 (tr) Yeni triazolo(4.5-D)pirimidin bileşimleri.
TR200000197T2 (tr) Yeni bileşimler
ATE217629T1 (de) Phosphonooxymethyl oder methylthiomethylether von taxanderivaten als antitumormittel
DE60227492D1 (de) Hemmstoffe der akt aktivität
FI933565A0 (fi) 7-(substituerad)-9-((substituerad glycyl)amido)-6-demetyl-6-deoxitetracykliner
HK1026691A1 (en) Substituted benzimidazoles and their use for treating retroviral infection
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
BR0014381A (pt) Derivados de 5-beta-sapogenina e pseudossapogenina e seu uso no tratamento de demência
TR200100448T2 (tr) Fenil ksantin türevleri
TR200000152T2 (tr) Yeni bileşikler.
IL162408A0 (en) Use of pramipexole to treat amyotrophic lateral scelrosis
HUP0300534A2 (hu) Tumorellenes ekteinaszcidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
NZ504487A (en) Combination of alpha-adrenergic antagonists and cGMP elevators for the treatment of impotence
TNSN99001A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques
DE69814135D1 (de) 7-substituierte chinazolin-2,4-dionen verwendbar als antibakterielle mittel
BG105256A (en) Muscarinic agonists and antagonists
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
GB2380939B (en) Treatment or prevention of auto-immune diseases
TR200101493T2 (tr) Eletriptan hidrobromid monohidrat
HUP0002836A2 (hu) Makrociklusos bisz(3,3'-indolil)-maleinimid-származékok alkalmazása bőrrendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
ITRM920305A0 (it) Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.
CA1263380C (en) MYCAMINOSYLTYLONOLIDE COMPOUNDS SUBSTITUTED FOR C-23 AND PHARMACEUTICAL COMPOUNDS CONTAINING THEM